Yang Jian-Qiang, Chen Xian-Yu, Engle Michelle Yixiao, Wang Jian-You
Department of Dermatology, Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
Department of Dermatology, First Affiliated Hospital of Huzhou University, Huzhou, Zhejiang, China.
Dermatol Ther. 2015 Jul-Aug;28(4):243-7. doi: 10.1111/dth.12217. Epub 2015 Mar 5.
Xeroderma pigmentosum (XP) is an autosomal recessive disease characterized by solar sensitivity, photophobia, early onset of freckling, and solar-induced cutaneous neoplastic changes. Management of patients with XP is a therapeutic challenge as they usually develop multiple cutaneous malignancies, making surgical therapy difficult, and continue to form skin malignancies at a high rate. We describe a 30-year-old Chinese man with XP who had been previously treated with excision and dermatoplasty. Upon recurrence of multiple superficial, ulcerative, and pigmented lesions, imiquimod 5% cream was recommended for 4 months. His multiple facial lesions demonstrated an excellent response to topical imiquimod 5% cream with minor side effects. This favorable response indicates that topical application of imiquimod 5% cream is an effective means of treating multiple basal cell carcinomas in XP.
着色性干皮病（XP）是一种常染色体隐性疾病，其特征为对日光敏感、畏光、早期出现雀斑以及日光诱导的皮肤肿瘤性改变。XP患者的治疗是一项具有挑战性的任务，因为他们通常会发生多发性皮肤恶性肿瘤，这使得手术治疗变得困难，并且皮肤恶性肿瘤仍会以较高的速率持续形成。我们描述了一名30岁的患有XP的中国男性，他此前曾接受过切除和皮肤成形术治疗。在多发性浅表、溃疡性和色素沉着性病变复发后，建议使用5%咪喹莫特乳膏治疗4个月。他面部的多处病变对局部应用5%咪喹莫特乳膏显示出极佳的反应，且副作用较小。这种良好的反应表明，局部应用5%咪喹莫特乳膏是治疗XP患者多发性基底细胞癌的一种有效方法。
